빅사레리맙 : 판매 예측 및 시장 규모(2034년)

Key Factors Driving Vixarelimab Growth

1. First-in-Class Dual IL-31 + OSM Pathway Inhibition

Vixarelimab is a fully human monoclonal antibody targeting the oncostatin M receptor B (OSMRB), thereby simultaneously inhibiting IL-31 (itch pathway) and oncostatin M (inflammation/fibrosis pathway).

• This dual mechanism is unique-most competitors target only IL-31.
• It addresses both pruritus and underlying skin pathology (nodules/fibrosis).
• Strong differentiation supports potential best-in-class positioning in prurigo nodularis (PN)
• Broader biological impact increases utility across inflammatory and fibrotic diseases

2. Robust Phase II Efficacy in Prurigo Nodularis

In a randomized Phase IIa trial:

• ~50.6% reduction in itch score vs ~29.4% placebo (p=0.03)
• ~30% of patients achieved clear/almost clear skin vs ~7.7% placebo (p=0.03)
• Rapid onset with significant improvement by Week 3
• Demonstrates clinically meaningful and rapid efficacy, a key driver of adoption in dermatology
• Supports advancement into later-stage trials and regulatory discussions

3. High Unmet Need in Prurigo Nodularis

• PN is a chronic, severely pruritic inflammatory disease with limited effective treatments historically.
• Patients suffer from intense itch, sleep disruption, and reduced quality of life.
• High unmet need enables:
• Fast uptake in specialty dermatology settings
• Potential for premium pricing and orphan-like positioning

4. Regulatory Momentum (Breakthrough Therapy Designation)

• The US FDA granted Breakthrough Therapy Designation (2020) for PN-associated pruritus.
• Accelerated development and review pathways
• Increased probability of faster time-to-market (if pivotal data are positive)

5. Pipeline Expansion into Fibrotic and Pulmonary Diseases

Vixarelimab is also being evaluated in:

• Systemic sclerosis-associated ILD (SSc-ILD)
• Idiopathic pulmonary fibrosis (IPF)
• Expands from dermatology -> multi-organ inflammatory/fibrotic diseases
• Significantly increases total addressable market beyond PN

6. Favorable Safety Profile Supporting Chronic Use

• Phase II data showed:
• No serious adverse events or discontinuations
• Comparable adverse event rates vs placebo

Vixarelimab Recent Developments

In August 2022, Kiniksa Pharmaceuticals announced a global license agreement with Roche and Genentech, a member of the Roche Group (Genentech), for the rights to develop and commercialize vixarelimab, a fully human monoclonal antibody targeting oncostatin M receptor beta (OSMRB).

"Vixarelimab Sales Forecast, and Market Size Analysis - 2034" report provides comprehensive insights of Vixarelimab for potential indication like Prurigo nodularis, Pruritus, and Ulcerative colitis in the 7MM. A detailed picture of Vixarelimab's existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 -2034 is provided in this report along with a detailed description of the Vixarelimab for potential indications. The Vixarelimab market report provides insights about Vixarelimab's sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current Vixarelimab performance, future market assessments inclusive of the Vixarelimab market forecast analysis for potential indications in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of Vixarelimab sales forecasts, along with factors driving its market.

Vixarelimab Drug Summary

Vixarelimab is an investigational, fully human monoclonal antibody designed to target the oncostatin M receptor beta (OSMRB), thereby inhibiting signaling from both interleukin-31 (IL-31) and oncostatin M (OSM), key cytokines involved in inflammation, pruritus (itch), and fibrosis. By blocking this shared receptor pathway, vixarelimab aims to address chronic pruritic and fibrotic skin conditions such as prurigo nodularis and other inflammatory dermatoses. Administered via subcutaneous injection, it has demonstrated promising results in early clinical trials, including significant reductions in itch severity and skin lesion burden, along with a generally favorable safety and tolerability profile. The drug remains under clinical development, with ongoing studies evaluating its long-term efficacy and broader therapeutic potential. The report provides Vixarelimab's sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the Vixarelimab Market Report

The report provides insights into:

• A comprehensive product overview including the Vixarelimab MoA, description, dosage and administration, research and development activities in potential indication like Prurigo nodularis, Pruritus, and Ulcerative colitis.
• Elaborated details on Vixarelimab regulatory milestones and other development activities have been provided in Vixarelimab market report.
• The report also highlights Vixarelimab's cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan.
• The Vixarelimab market report also covers the patents information, generic entry and impact on cost cut.
• The Vixarelimab market report contains current and forecasted Vixarelimab sales for potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The Vixarelimab market report also features the SWOT analysis with analyst views for Vixarelimab in potential indications.

Methodology:

The Vixarelimab market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Vixarelimab Analytical Perspective by DelveInsight

• In-depth Vixarelimab Market Assessment

This Vixarelimab sales market forecast report provides a detailed market assessment of Vixarelimab for potential indication like Prurigo nodularis, Pruritus, and Ulcerative colitis in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted Vixarelimab sales data uptil 2034.

• Vixarelimab Clinical Assessment

The Vixarelimab market report provides the clinical trials information of Vixarelimab for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

Vixarelimab Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

Vixarelimab Market Potential & Revenue Forecast

• Projected market size for the Vixarelimab and its key indications
• Estimated Vixarelimab sales potential (Vixarelimab peak sales forecasts)
• Vixarelimab Pricing strategies and reimbursement landscape

Vixarelimab Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• Vixarelimab Market positioning compared to existing treatments
• Vixarelimab Strengths & weaknesses relative to competitors

Vixarelimab Regulatory & Commercial Milestones

• Vixarelimab Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

Vixarelimab Clinical Differentiation

• Vixarelimab Efficacy & safety advantages over existing drugs
• Vixarelimab Unique selling points

Vixarelimab Market Report Highlights

• In the coming years, the Vixarelimab market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The Vixarelimab companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Vixarelimab's dominance.
• Other emerging products for Prurigo nodularis, Pruritus, and Ulcerative colitis are expected to give tough market competition to Vixarelimab and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Vixarelimab in potential indications.
• Analyse Vixarelimab cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted Vixarelimab sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of Vixarelimab in potential indications.

Key Questions:

• What is the class of therapy, route of administration and mechanism of action of Vixarelimab? How strong is Vixarelimab's clinical and commercial performance?
• What is Vixarelimab's clinical trial status in each individual indications such as Prurigo nodularis, Pruritus, and Ulcerative colitis and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Vixarelimab Manufacturers?
• What are the key designations that have been granted to Vixarelimab for potential indications? How are they going to impact Vixarelimab's penetration in various geographies?
• What is the current and forecasted Vixarelimab market scenario for potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of Vixarelimab in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to Vixarelimab for potential indications?
• Which are the late-stage emerging therapies under development for the treatment of potential indications?
• How cost-effective is Vixarelimab? What is the duration of therapy and what are the geographical variations in cost per patient?

Table of Contents

1. Report Introduction

2. Vixarelimab Overview in potential indication like Prurigo nodularis, Pruritus, and Ulcerative colitis

• 2.1. Product Detail
• 2.2. Vixarelimab Clinical Development
  • 2.2.1. Vixarelimab Clinical studies
  • 2.2.2. Vixarelimab Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Vixarelimab Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Vixarelimab Therapies)

5. Vixarelimab Market Assessment

• 5.1. Vixarelimab Market Outlook in potential indications
• 5.2. 7MM Analysis
  • 5.2.1. Vixarelimab Market Size in the 7MM for potential indications
• 5.3. Country-wise Market Analysis
  • 5.3.1. Vixarelimab Market Size in the United States for potential indications
  • 5.3.2. Vixarelimab Market Size in Germany for potential indications
  • 5.3.3. Vixarelimab Market Size in France for potential indications
  • 5.3.4. Vixarelimab Market Size in Italy for potential indications
  • 5.3.5. Vixarelimab Market Size in Spain for potential indications
  • 5.3.6. Vixarelimab Market Size in the United Kingdom for potential indications
  • 5.3.7. Vixarelimab Market Size in Japan for potential indications

6. Vixarelimab SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options